These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20309563)

  • 1. Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.
    Funahashi Y; Hattori R; Matsukawa Y; Komatsu T; Sassa N; Gotoh M
    World J Urol; 2011 Apr; 29(2):225-31. PubMed ID: 20309563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Masumori N; Hashimoto J; Itoh N; Tsukamoto T;
    Scand J Urol Nephrol; 2007; 41(5):422-9. PubMed ID: 17853040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study.
    Chung MS; Yoon BI; Lee SH
    Yonsei Med J; 2017 Jul; 58(4):800-806. PubMed ID: 28540994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Yamaguchi S; Osanai H; Numata A; Watanabe M; Kakizaki H
    Int J Urol; 2013 May; 20(5):513-9. PubMed ID: 23078534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
    Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
    Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia.
    Funahashi Y; Hattori R; Yoshino Y; Matsukawa Y; Sassa N; Gotoh M
    Low Urin Tract Symptoms; 2011 Sep; 3(2):113-7. PubMed ID: 26676397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
    Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
    Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
    Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
    Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
    Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia].
    Hanyu S; Hatano A; Nishiyama T; Obara K; Takahashi K
    Hinyokika Kiyo; 2010 Sep; 56(9):489-94. PubMed ID: 20940522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia].
    Hayashi T; Sakai Y; Saito K; Arai G; Hyochi N; Suzuki M; Masuda H; Kawakami S; Okuno T; Kobayashi T; Kageyama Y; Kihara K
    Hinyokika Kiyo; 2002 Jan; 48(1):7-11. PubMed ID: 11868386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
    Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
    Kosugi S; Ikemoto I; Furuta A; Shimomura T; Kiyota H; Suzuki Y; Kishimoto K; Egaway S; Torii S; Shirai H; Takeuchi H; Abe K
    Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):691-9. PubMed ID: 17682448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
    Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.